ORDER GAD FOR PRECLINICAL RESEARCH ABOUT US DIABETES PRODUCT DEVELOPMENT CLINICAL TRIALS INVESTORS INVESTERARE (SE) Företrädesemission i Diamyd Medical AB Information om emissionen Press Releases June 9, 2017 New interim report for Diamyd® directly into the lymph node indicates continued positive clinical course 9 juni, 2017 Ny delrapport för Diamyd® direkt i lymfkörtel indikerar fortsatt positivt kliniskt förlopp Events & Mediawatch June 1, 2017 Sweden ”Vägen öppen efter emissionen” Nyhetsbyrån Direkt intervjuar vd Ulf Hannelius Calendar June 9, 2017 ADA Scientific Sessions American Diabetes Association 77th Scientific Sessions, San Diego, USA June 28, 2017 Quarterly Report III Quarterly Report 3 2016/2017 October 11, 2017 Financial Statement Financial Statement 2016/2017 Financial Reports April 5, 2017 Quarterly Report II 16/17 5 april 2017 Delårsrapport II 16/17 Our discussions with major multinational companies continue, and the established path forward with our GAD and GABA projects has created a significantly stronger negotiation position. ULF HANNELIUS President and CEO, Diamyd Medical AB Read More THE COMPANY Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development The share is listed on Nasdaq Stockholm First North (ticker: DMYD B) Read More Read more Diabetes More than 400 million people worldwide suffer from diabetes. 10-20% have an autoimmune form of the disease where the immune system attacks and destroys the insulin-producing beta cells. Autoimmune diabetes is a chronic disease and there is currently no cure. Read more Product Development Diamyd Medical develops the diabetes vaccine Diamyd®, based on the exclusively licensed GAD molecule. The Company’s licensed technologies GABA and Gliadin also have the potential to become key pieces of the puzzle to prevent, treat or cure autoimmune diabetes. Read more Clinical Trials The development of Diamyd Medical’s licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in clinical trials and preclinical studies. Six clinical trials are currently ongoing. Annual Report November 3, 2016 Download Contact Us Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden +46 8 661 00 26 +46 8 661 63 68 info@diamyd.com Subscribe Follow Us © 2016 Cookies/Privacy | Site Information Share This Page